top of page
  • Active, not recruiting

NCT05014412: Phase 1/2: Elranatamab in MM That Has Come Back or Has not responded - MagnetisMM-9

Updated: Feb 10

  • MagnetisMM-9

  • NCT05014412: Phase 1/2: A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment (MagnetisMM-9)


MagnetisMM9

A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment (MagnetisMM-9)


The purpose of this study is to evaluate the safety of a step-up dosing approach (starting with low doses followed by higher doses) of the study medicine (elranatamab) in participants with multiple myeloma that has come back after responding to treatment or has not responded to treatment (relapsed/refractory multiple myeloma). This study will also look at the safety and efficacy of different doses of elranatamab, as well as different intervals between doses.


Participants in the study will receive elranatamab as an injection under the skin at the study clinic. After the initial step-up doses, participants will start receiving one dose every week. The frequency of clinic visits for injections may then decrease over time. Participation will be at least two years.


Sponsor

 

ClinicalTrials.gov Identifier: NCT05014412

Official Title: A PHASE 1/2, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE A DOSING REGIMEN WITH TWO STEP-UP PRIMING DOSES AND LONGER DOSING INTERVALS OF ELRANATAMAB (PF-06863135) MONOTHERAPY IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

First Posted : August 20, 2021

Click here for details on Clinicaltrials.gov


 

Elranatamab (Code C146860)

Anti-CD3/Anti-BCMA Bispecific Antibody PF-06863135

B-cell Maturation Antigen-CD3 Bispecific Antibody PF-06863135

BCMA x CD3 Bispecific Antibody PF-06863135

BCMA-CD3 Bispecific Ab PF-06863135

Elranatamab

ELRANATAMAB

PF 06863135

PF-06863135

PF06863135

RN 613

RN-613

RN613

 

Locations

United States, Colorado

United States, Florida

United States, Kentucky

United States, Louisiana

United States, Michigan

United States, Ohio

United States, Texas

United States, Utah


Europe

United Kingdom

Asia

Japan

Taiwan

 

RELATED POSTS


MagnetisMM-1

NCT03269136: Phase 1 -PF-06863135 As Single Agent & with Immunomodulatory Agents In relapsed Myeloma - MagnetisMM-1


MAGNETISMM-2

NCT04798586: Phase 1: Study of Elranatamab (PF-06863135) in Japanese Patients Myeloma - MAGNETISMM-2


MagnetisMM-3

NCT04649359: Phase 2: Elranatamab (PF-06863135) Monotherapy in relapsed Myeloma - MagnetisMM-3


MagnetisMM-4

NCT05090566: Phase 2: Umbrella Study of Elranatamab (PF-06863135) + Anti-Cancer Tx RRMM - MagnetisMM-4


MagnetisMM-5

NCT05020236: Phase 3: Elranatamab (PF-06863135) Vs & Elranatamab/Dara VS Dara/Pom/Dex - MagnetisMM-5


MagnetisMM-7

NCT05317416: Phase 3: Elranatamab Versus Lenalidomide in Patients With NDMM post ASCT - MagnetisMM-7


MagnetisMM-8

NCT05228470: Phase 2: Study Of Elranatamab (PF-06863135) Monotherapy in China RRMM - MagnetisMM-8


NCT05238311: Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135)







Bình luận


Bình luận đã bị tắt.
Posts Archive
bottom of page